Download PDF
Thromb Haemost 1981; 45(03): 282-284
DOI: 10.1055/s-0038-1650188
Original Article
Schattauer GmbH Stuttgart

Measurement of Fibrinopeptide A in Patients Treated with Phenoprocoumon[*]

J Harenberg
The Department of Clinical Pharmacology and Internal Medicine I, Medical Clinic, University of Heidelberg, West Germany
,
R Haas
The Department of Clinical Pharmacology and Internal Medicine I, Medical Clinic, University of Heidelberg, West Germany
,
R Zimmermann
The Department of Clinical Pharmacology and Internal Medicine I, Medical Clinic, University of Heidelberg, West Germany
› Author Affiliations
Further Information

Publication History

Received 02 December 1980

Accepted 23 April 1981

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Fibrinopeptide A (FPA), which is considered to be a quantitative indicator for the thrombin activity in vivo, was measured in 136 patients treated with phenprocoumon in order to obtain information on the effectiveness of the inhibition of the coagulation system. The results show a decrease of the FPA concentration in relation to the efficacy of the anticoagulant therapy as measured by the thrombotest coagulation method (p<0.01). However, elevated FPA was observed even under an effective oral anticoagulation.

These data indicate that an increased thrombin activity cannot be completely prevented by oral anticoagulants in every patient. Combined measurement of FPA and the thrombotest coagulation method might be used to detect patients with an elevated risk of recurrent thromboembolism despite treatment with phenprocoumon.

Keywords

Fibrinopeptide A - Antithrombotic therapy - Oral anticoagulants - Phenprocoumon - Hypercoagulability of plasma

* Supported by grants from the “Deutsche Forschungsgemeinschaft”


 

  • References

  • 1 Dick W, Matis P, Mayer W. Results of alternating anticoagulant prophylaxis in surgery. Thrombos Diathes Haemorrh 1959; 03: 11-19
    PubMedGoogle Scholar
  • 2 Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Eng J Med 1979; 301: 855-858
    CrossrefPubMedGoogle Scholar
  • 3 Loeliger EA, Henssen A, Kroes F, van DijkL M, Fekkes N, de JongeH, Hemker HC. A double-blind trial of long-term anticoagulent treatment after myocardial infarction. Acta Med Scand 1967; 182: 549-565
    PubMedGoogle Scholar
  • 4 Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980; 09: 325-344
    PubMedGoogle Scholar
  • 5 Nossel HL, Younger LR, Milner GD, Procupez T, Canfield RE, Butler VP. Radioimmunoassay of human fibrinopeptide A. Proc Nat Acad Sri 1971; 68: 2350-2353
    PubMedGoogle Scholar
  • 6 Gerrits WB J, Flier O, van derMeer J. Fibrinopeptide A immunoreactivity in human plasma. Thromb Res 1974; 05: 197-212
    CrossrefPubMedGoogle Scholar
  • 7 Budzinski AZ, Marder VJ. Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood. Thrombos Diathes Haemorrh 1975; 34: 709-717
    PubMedGoogle Scholar
  • 8 Cronlund M, Hardin J, Burton J, Lee L, Haber E, Block KJ. Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematodes. J Clin Invest 1976; 58: 142-151
    CrossrefPubMedGoogle Scholar
  • 9 Kockum C. Radioimmunoassay of fibrinopeptide A. Clinical Application. Thromb Res 1977; 11: 171-181
    CrossrefPubMedGoogle Scholar
  • 10 Harenberg H, Hepp G, Schmidt-Gayk H. Fibrinopeptide A in human plasma-evaluation of a new radioimmunoassay technique on microliter plates. Thromb Res 1979; 15: 513-522
    CrossrefPubMedGoogle Scholar
  • 11 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 12 Owren PA. Thrombotest – a new method for controlling anticoagulant therapy. Lancet 1959; 02: 754-758
    PubMedGoogle Scholar
  • 13 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-241
    CrossrefPubMedGoogle Scholar
  • 14 Nossel HL, Butler VP, Canfield RE, Yudelman I, Spanondis MK, Soland T. Potential use of fibrinopeptide A measurements in the diagnosis and management of thrombosis. Thrombos Diathes Haemorrh 1975; 33: 426-434
    PubMedGoogle Scholar
  • 15 Yudelman IM, Nossel HL, Kaplan KL, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189-1195
    PubMedGoogle Scholar
  • 16 Peuscher FW, van AkenW G, Flier ThN, Stoepman-van DalemE A, Cremer-Goote TM, van MourikJ A. Effects of anticoagulant treatment measured by fibrinopeptide A in patients with venous thromboembolism. Thromb Res 1980; 18: 33-43
    CrossrefPubMedGoogle Scholar
  • 17 Johnsson H, Orinius E, Paul Ch. Fibrinopeptide A in patients with acute myocardial infarction. Thromb Res 1979; 16: 255-260
    CrossrefPubMedGoogle Scholar
  • 18 Harenberg J, Zimmermann R, Haas R, Schmidt-Gayk H. A new radioimmunoassay-technique for fibrinopeptide A in human plasma. Thromb Haemostas 1979; 42: 98 Abstract
    PubMedGoogle Scholar
  • 19 Leoliger EA, Mattem MJ, den BrabanderA S A. Behavior of factors II, VII, IX, X during long-term treatment with cumarin. Thrombos Diathes Haemorrh 1963; 09: 74-83
    PubMedGoogle Scholar
  • 20 Bertina RM, van derMaral-van Nieuwkoop W, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemostas 1979; 42: 1296-1305
    PubMedGoogle Scholar
  • 21 Deutsch E. Klinische Anwendung der Anticoagulantien. In: Anticoagulantien. Ed. Markwardt F. Handbuch der experimentellen Pharmakologie, Springer Verlag Heidelberg. 1971
    Google Scholar